Stilbene derivatives for ADP-ribosyl cyclase inhibitors
US8314082B2 · kind B2 · utility
0Cited by
5References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2011 |
| Grant date | Nov 20, 2012 |
| Priority date | — |
| Expiry date | May 31, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C39/215
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.